Rimadyl Tablets 50 mg

Ülke: Birleşik Krallık

Dil: İngilizce

Kaynak: VMD (Veterinary Medicines Directorate)

Aktif bileşen:

Carprofen

Mevcut itibaren:

Pfizer Ltd

ATC kodu:

QM01AE91

INN (International Adı):

Carprofen

Yetkilendirme durumu:

Expired

Ürün özellikleri

SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Rimadyl Tablets 50mg
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 50mg Carprofen
For the full list of all other excipients see section 6.1
3.
PHARMACEUTICAL FORM
Tablets.
4. CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For analgesia and reduction of chronic inflammation, for example in
degenerative
joint disease, in the dog.
Rimadyl tablets can also be used in the management of post-operative
pain.
4.3 CONTRAINDICATIONS
Do not exceed the stated dose.
The elimination time of NSAIDs, including carprofen, in the cat is
longer than in the dog and the therapeutic index is narrower. In
the absence of specific data the use of Rimadyl Tablets in the cat
is contra-indicated.
Do not use in dogs suffering from cardiac, hepatic or renal disease,
where there is a
possibility of gastro-intestinal ulceration or bleeding, or where
there is evidence of
blood dyscrasia or hypersensitivity to the product. As with other
NSAIDs there is a
risk of rare idiosyncratic renal or hepatic adverse events.
Do not administer other NSAIDs concurrently or within 24 hours of each
other.
Some NSAIDs may be highly bound to plasma proteins and compete with
other
highly bound drugs, which can lead to toxic effects.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Use in dogs less than 6 weeks of age, or in aged dogs, may involve
additional risk.
If such a use cannot be avoided, such dogs may require a reduced
dosage and
careful clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive dog,
as there is a potential rise of increased renal toxicity.
Concurrent administration of potential nephrotoxic drugs should be
avoided.
NSAID’s can cause inhibition of phagocytosis and hence in the
treatment of
inflammatory conditions associated with bacterial infection,
appropriate concurrent
antimicrobial therapy should